What is Denali Therapeutics Inc.'s debt issuance costs?

Denali Therapeutics Inc. (DNLI) reported debt issuance costs of $81K in Q4 2025.

What does debt issuance costs mean?

Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.

Denali Therapeutics Inc. DNLI Debt Issuance Costs

Debt Issuance Costs at other companies

Dyne Therapeutics, Inc.DYN

$30K—

Beam TherapeuticsBEAM

$813K—

BioCryst PharmaceuticalsBCRX

$4.95M—

BridgeBio PharmaBBIO

——

BioMarin PharmaceuticalsBMRN

——

Other financials

Income statement

See full

Revenue-—

Operating income-$137.4M+5.6%

Net income-$128.4M+3.4%

EPS (diluted)-$0.69+11.5%

Balance sheet

See full

Cash & equivalents$390.7M+551%

Total debt$40.0M-22.3%

Total equity$926.1M-17.5%

Total assets$1.3B-0.4%

Cash flow

See full

Operating cash flow-$131.2M+0.2%

CapEx$2.5M-51.4%

Free cash flow-$133.7M+2.1%

Valuation

See full

Market cap$3.93B+54.2%

Profitability

See full

Operating margin-37,938%-37,986pp

Net margin-33,121.9%-33,159pp

FCF margin-31,736.3%-31,830pp

Returns & leverage

See full

Return on equity-49.6%+34.2pp

Debt / equity0×0.0×

Current ratio9.3×-0.3×

Where this comes from

Reported directly by Denali Therapeutics Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsOfFinancingCosts.

The official record: Denali Therapeutics Inc.’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Denali Therapeutics Inc.'s debt issuance costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Denali Therapeutics Inc.'s debt issuance costs?: Denali Therapeutics Inc. (DNLI) reported debt issuance costs of $81K in Q4 2025.
What does debt issuance costs mean?: Cash paid for fees, legal costs, and underwriting discounts associated with issuing new debt.